Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04900935 · ClinicalTrials.gov registry record · NA

Patient-centered, Optimal Integration of Survivorship and Palliative Care

A NA study of Non-Small Cell Lung Cancer and Carcinoma, Non-Small Cell Lung, sponsored by Massachusetts General Hospital.

Recruiting
Registry status
NA
Development phase
70
Enrollment target
1
Study location

NCT04900935: Recruiting NA study of Non-Small Cell Lung Cancer and Carcinoma, Non-Small Cell Lung, sponsored by Massachusetts General Hospital.

NCT04900935 is a NA study of Non-Small Cell Lung Cancer and Carcinoma, Non-Small Cell Lung that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 70 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04900935, a NA study of Non-Small Cell Lung Cancer and Carcinoma, Non-Small Cell Lung, is actively recruiting participants, sponsored by Massachusetts General Hospital.

RECRUITING
Registry status
NA
Development phase
70 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to develop and test the feasibility of a supportive care model (POISE) for patients with metastatic Non-small Cell Lung Cancer (NSCLC). The main questions are * is POISE feasible to deliver and acceptable to patients * what is the effect of POISE on the distress patients feel related to their uncertain future, their confidence in their ability to manage cancer, and their understanding about what to expect Participants in the randomized controlled trial will receive either the new supportive care model, POISE, which consists of four visits with a trained palliative care clinician, or care as usual, and will be asked to complete three surveys.

Primary Outcome

≥60% enrollment among eligible patientsamong patients in the POISE group

Interventions

  • BEHAVIORAL POISE

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2023-09-29
Est. Completion 2027-09-01
Phase NA
Massachusetts General Hospital

2,032 total trials

What NCT04900935 shows while recruiting

NCT04900935 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (89% lower).

The record links to 8 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which POISE is the first listed.

NCT04900935 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04900935 about?

NCT04900935 is a clinical study titled "Patient-centered, Optimal Integration of Survivorship and Palliative Care". The goal of this study is to develop and test the feasibility of a supportive care model (POISE) for patients with metastatic Non-small Cell Lung Cancer (NSCLC). The main questions are * is POISE feasible to deliver and acceptable to patients * what is the effect of POISE on the distress patients f...

What is the current status of trial NCT04900935?

This trial is currently recruiting. It is a NA study. The enrollment target is 70 participants. The study started on 2023-09-29. Estimated completion is 2027-09-01.

What conditions does trial NCT04900935 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Survivorship, Stage IV Non-small Cell Lung Cancer, Palliative Care.

What interventions are being tested in trial NCT04900935?

The interventions under investigation include: POISE (BEHAVIORAL).

Who is sponsoring clinical trial NCT04900935?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04900935 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04900935's enrollment target sits among peer trials

70 289th of 454 higher than 161 of 454 other Non-Small Cell Lung Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00969111 · 70 participants · NA

    Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy

  • NCT01712620 · 70 participants · Phase 2

    Spironolactone for Pulmonary Arterial Hypertension

  • NCT02143830 · 70 participants · Phase 2

    HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

  • NCT02601339 · 70 participants

    NIRS Monitoring in Premature Infants

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04900935, the US trial registry maintained by the National Library of Medicine. NCT04900935 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.